Tetanus primer significantly improves survival after immunotherapy for glioblastoma
the ONA take:
A study led by Duke Cancer Institute researchers demonstrated that an innovative pretreatment can enhance the effectiveness of immunotherapy for glioblastoma, dramatically improving patient survival.
Earlier research findings showed that glioblastoma tumors harbor a strain of cytomegalovirus (CMV) not present in the brain tissue around the tumor. This provides a natural target for immunotherapy.
Using dendritic cells, the researchers created a vaccine for the tumor. Patients with glioblastoma typically survive for little more than 1 year after diagnosis; however, after receiving the immunotherapy, half lived nearly 5 years or longer from their diagnosis.
Looking to expand on the effectiveness of the treatment, the researchers chose to use a shot of tetanus/diphtheria toxoid to incite the patient’s immune system.
In a blinded trial involving 12 patients with brain tumor, half were randomly selected to receive the tetanus shot; the other half received a placebo injection. The patients who received the tetanus shot had significantly longer survival than those who received the dendritic cell therapy alone (51-101 months vs 11.6 months).
One patient in the tetanus group continues to show no tumor growth and is still alive 8 years after the treatment.
An innovative pretreatment can enhance the effectiveness of immunotherapy for glioblastoma, dramatically improving patient survival.
- Immunotherapy May Benefit Some Patients with Papillary Thyroid Carcinoma
- New Study Questions Standard Dosage for Treating Metastatic Non-Small Cell Lung Cancer
- Superior Tolerability, Efficacy With Alectinib in Treatment-Naïve ALK-poistive NSCLC
- Adding Pertuzumab to Adjuvant Therapy Is Beneficial for Some Women with Early Breast Cancer
- Clinical Trials May Benefit Oncology Patients
- Survivorship Care Plans: Providing A Blueprint for Health Care After Cancer
- Cancer Recurrence Fear Reduced by Novel Psychological Intervention
- Multifaceted Role of the Nurse Navigator Includes Palliative, Supportive Care
- Patient Navigators Found to Boost Lung Cancer Screening Rates
- Breast Cancer Diagnosis and Nurse Navigation Survey
- Radiotherapy is Essential in Treating Brain Tumors But Associated With Significant Adverse Events
- Prostate-specific PET and CT Imaging Improves Detection of Disease and Patient Care
- Lenvatinib Improves OS, PFS in Radioiodine-Refractory Differentiated Thyroid Cancer in All Older Patients
- Breast Cancer Overdiagnosis Also a Result of Screening Mammography Programs
- Use of Aspirin, NSAIDs Correlates with Improved Overall Survival in Colorectal Cancer
Sign Up for Free e-newsletters
Regimen and Drug Listings
GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION
|Head and Neck Cancer||Regimens||Drugs|